$RMTG
Regenerative Medical Technology Group Inc. Stock $rmtg

$rmtg Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000121390024069065 Filed on August 14, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q4
Revenue	$986.3K	$793.3K	$615.6K
YoY Change	52.48%	119.54%	13.73%
Cost Of Revenue	$239.2K	$266.4K	$180.8K
YoY Change	21.73%	147.78%	-1.95%
Gross Profit	$747.1K	$526.9K	$434.8K
YoY Change	65.91%	107.58%	21.83%
Gross Profit Margin	75.74%	66.41%	70.63%
Selling, General & Admin		$657.9K	$472.9K
YoY Change		4.96%	12.3%
% of Gross Profit		124.86%	108.78%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$82.97K	$96.93K
YoY Change		43.36%	91.71%
% of Gross Profit		15.75%	22.3%
Operating Expenses	$727.4K	$740.9K	$569.9K
YoY Change	38.46%	8.21%	20.81%
Operating Profit	$19.65K	-$214.0K	-$135.1K
YoY Change	-126.18%	-50.33%	17.66%
Interest Expense		-$1.863M	-$1.632M
YoY Change		16.46%	72.56%
% of Operating Profit
Other Income/Expense, Net	-$906.8K		$2.460K
YoY Change	-45.29%
Pretax Income		-$2.077M	-$256.0K
YoY Change		2.29%	-75.86%
Income Tax
% Of Pretax Income
Net Earnings	-$887.1K	-$2.077M	-$256.0K
YoY Change	-84.85%	2.29%	-74.2%
Net Earnings / Revenue	-89.95%	-261.76%	-41.59%
Basic Earnings Per Share	-$0.07	-$0.17
Diluted Earnings Per Share	-$0.07	-$0.17	-$0.02
COMMON SHARES
Basic Shares Outstanding	12.54M shares	12.49M shares	12.44M shares
Diluted Shares Outstanding	12.54M shares	12.49M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments		$617.1K	$530.5K
YoY Change		-49.63%	-67.75%
Cash & Equivalents	$836.4K	$617.1K	$530.5K
Short-Term Investments
Other Short-Term Assets		$38.61K	$20.50K
YoY Change
Inventory	$6.680K	$6.680K
Prepaid Expenses	$43.07K	$38.61K	$20.50K
Receivables		$24.19K	$23.96K
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$917.2K	$686.6K	$575.0K
YoY Change	-22.91%	-46.21%	-66.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$349.5K	$360.3K	$359.3K
YoY Change	136.4%	175.61%	92.89%
Goodwill	$1.680M	$1.680M	$1.680M
YoY Change	0.0%	-71.06%	-71.06%
Intangibles	$183.4K	$207.8K	$256.5K
YoY Change	-34.72%	-31.95%	-27.55%
Long-Term Investments
YoY Change
Other Assets	$7.264K	$7.264K	$5.568K
YoY Change	30.41%	30.41%	-0.04%
Total Long-Term Assets	$2.311M	$2.364M	$2.304M
YoY Change	8.75%	-62.28%	-63.92%
TOTAL ASSETS
Total Short-Term Assets	$917.2K	$686.6K	$575.0K
Total Long-Term Assets	$2.311M	$2.364M	$2.304M
Total Assets	$3.228M	$3.050M	$2.879M
YoY Change	-2.61%	-59.56%	-64.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.103M	$562.2K	$421.3K
YoY Change	200.43%	66.88%	71.65%
Accrued Expenses	$8.898M	$8.207M	$6.597M
YoY Change	25.67%	31.56%	41.65%
Deferred Revenue	$79.85K	$372.9K	$2.000K
YoY Change
Short-Term Debt		$0.00	$0.00
YoY Change
Long-Term Debt Due		$17.27M	$15.22M
YoY Change		143.47%	116.04%
Total Short-Term Liabilities	$27.49M	$26.42M	$22.25M
YoY Change	12.53%	92.94%	85.42%
LONG-TERM LIABILITIES
Long-Term Debt		$2.434M	$2.425M
YoY Change		-74.46%	-69.91%
Other Long-Term Liabilities		$32.07K	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities		$2.467M	$2.425M
YoY Change		-74.13%	-69.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.49M	$26.42M	$22.25M
Total Long-Term Liabilities		$2.467M	$2.425M
Total Liabilities	$29.95M	$28.88M	$24.67M
YoY Change	20.49%	24.36%	22.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$66.91M	-$66.03M	-$61.99M
YoY Change	8.39%	18.17%	18.81%
Common Stock	$12.54K	$12.49K	$12.49K
YoY Change	0.76%	0.4%	0.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$26.72M	-$25.83M	-$21.80M
YoY Change
Total Liabilities & Shareholders Equity	$3.228M	$3.050M	$2.879M
YoY Change	-2.61%	-59.56%	-64.37%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q4
OPERATING ACTIVITIES
Net Income	-$887.1K	-$2.077M	-$256.0K
YoY Change	-84.85%	2.29%	-74.2%
Depreciation, Depletion And Amortization		$82.97K	$96.93K
YoY Change		43.36%	91.71%
Cash From Operating Activities		$90.39K	-$29.40K
YoY Change		-122.22%	-40.52%
INVESTING ACTIVITIES
Capital Expenditures		$52.66K	$284.0K
YoY Change		1015.68%	314.43%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$52.66K	-$284.0K
YoY Change		1015.68%	314.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000	-300.0K
YoY Change			4515.38%
NET CHANGE
Cash From Operating Activities		90.39K	-29.40K
Cash From Investing Activities		-52.66K	-284.0K
Cash From Financing Activities		0.000	-300.0K
Net Change In Cash		37.73K	-613.4K
YoY Change		-109.17%	392.86%
FREE CASH FLOW
Cash From Operating Activities		$90.39K	-$29.40K
Capital Expenditures		$52.66K	$284.0K
Free Cash Flow		$37.73K	-$313.4K
YoY Change		-109.17%	165.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12443938	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12493938	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12493938	shares
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	46715251	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	126884881	shares
CY2024Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	4352	usd
CY2024Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	4352	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2146	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2146	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-56010
	dei	Entity Registrant Name EntityRegistrantName	MESO NUMISMATICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	88-0492191
	dei	Entity Address Address Line1 EntityAddressAddressLine1	433 Plaza Real Suite 275
	dei	Entity Address City Or Town EntityAddressCityOrTown	Boca Raton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33432
	dei	City Area Code CityAreaCode	(800)
	dei	Local Phone Number LocalPhoneNumber	889-9509
	dei	No Trading Symbol Flag NoTradingSymbolFlag	true
	dei	Security12b Title Security12bTitle	None
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12538968	shares
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	617093	usd
CY2024Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	24188	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	6680	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	38610	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	686571	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	360341	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7264	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	207774	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	108158	usd
CY2024Q2	us-gaap	Goodwill Goodwill	1679978	usd
CY2024Q2	us-gaap	Assets Assets	3050085	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	562188	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	421334	usd
CY2024Q2	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	8130464	usd
CY2023Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	6597422	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	372860	usd
CY2024Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	4352	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	76092	usd
CY2024Q2	us-gaap	Notes Payable Current NotesPayableCurrent	17270761	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	26416717	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	32066	usd
CY2024Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	39981	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	35023	usd
CY2024Q2	mssv	Notes Payable Net Of Discount NotesPayableNetOfDiscount	2386664	usd
CY2024Q2	us-gaap	Liabilities Liabilities	28883228	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	6500000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12493938	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12493938	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	12494	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	40181074	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66027771	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-25833143	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3050085	usd
CY2024Q2	us-gaap	Revenues Revenues	793329	usd
CY2023Q2	us-gaap	Revenues Revenues	361359	usd
	us-gaap	Revenues Revenues	1610363	usd
	us-gaap	Revenues Revenues	1147557	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	266445	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	107535	usd
	us-gaap	Cost Of Revenue CostOfRevenue	514488	usd
	us-gaap	Cost Of Revenue CostOfRevenue	356932	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	526884	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	253824	usd
	us-gaap	Gross Profit GrossProfit	1095875	usd
	us-gaap	Gross Profit GrossProfit	790625	usd
CY2024Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	97175	usd
CY2023Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	114811	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	241458	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	256448	usd
CY2024Q2	us-gaap	Professional Fees ProfessionalFees	253008	usd
CY2023Q2	us-gaap	Professional Fees ProfessionalFees	255412	usd
	us-gaap	Professional Fees ProfessionalFees	501390	usd
	us-gaap	Professional Fees ProfessionalFees	464783	usd
CY2024Q2	us-gaap	Labor And Related Expense LaborAndRelatedExpense	22500	usd
CY2023Q2	us-gaap	Labor And Related Expense LaborAndRelatedExpense	22500	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	45000	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	45000	usd
CY2024Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	82971	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	57875	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	159543	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	114503	usd
CY2024Q2	mssv	Investor Relation InvestorRelation	23174	usd
CY2023Q2	mssv	Investor Relation InvestorRelation	2250	usd
	mssv	Investor Relation InvestorRelation	46442	usd
	mssv	Investor Relation InvestorRelation	4500	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	262036	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	231817	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	421127	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	410443	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	740863	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	684665	usd
	us-gaap	Operating Expenses OperatingExpenses	1414961	usd
	us-gaap	Operating Expenses OperatingExpenses	1295677	usd
CY2024Q2	us-gaap	Interest Expense Other InterestExpenseOther	1861931	usd
CY2023Q2	us-gaap	Interest Expense Other InterestExpenseOther	1600380	usd
	us-gaap	Interest Expense Other InterestExpenseOther	3716348	usd
	us-gaap	Interest Expense Other InterestExpenseOther	3200806	usd
CY2024Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-708	usd
CY2023Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	998	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2206	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2925	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	2463	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2076620	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2030223	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4037640	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3700470	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.3
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12493938	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12443938	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12493938	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12443938	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-21795503	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4037640	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-25833143	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-25756523	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2076620	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-25833143	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-11982292	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3700470	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-15682762	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-13652539	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2030223	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-15682762	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4037640	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3700470	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2056217	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1531096	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	159543	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	114503	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2206	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2925	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	2463	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	232	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1495	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	18110	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6680	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1696	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2044755	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1661816	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	198364	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-399938	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	111811	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10207	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-111811	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10207	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	9850	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-9850	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	86553	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-419995	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	530540	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1645185	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	617093	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1225190	usd
	mssv	Going Concern GoingConcern	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Going Concern</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception, resulting in an accumulated deficit of $66,027,771 and a working capital deficit of $25,730,147 as of June 30, 2024 and future losses are anticipated. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The ability of the Company to continue its operations as a going concern is dependent on management’s plans, which include the raising of capital through debt and/or equity markets with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company will require additional funding to finance the growth of its current and expected future operations as well to achieve its strategic objectives. There can be no assurance that financing will be available in amounts or terms acceptable to the Company, if at all. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p>
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66027771	usd
CY2024Q2	mssv	Working Capital Deficit WorkingCapitalDeficit	25730147	usd
	us-gaap	Revenues Revenues	1610363	usd
	us-gaap	Revenues Revenues	1147557	usd
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On July 2, 2018, the Board of Directors authorized and shareholders approved a 1-for-1,000 reverse stock split of the Company’s issued and outstanding shares of common stock held by the holders of record.
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Use of Estimates in Financial Statement Presentation</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The significant estimates included in these financial statements are associated with accounting for the goodwill, derivative liability, valuation of preferred stock, and for the valuation of assets and liabilities in business combination.</span></p>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Reclassifications</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Certain amounts for the prior year have been revised or reclassified to conform to the current year presentation. No change in net loss resulted from these reclassifications.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i> </i></span></p>
	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1639863	usd
	us-gaap	Cost Of Revenue CostOfRevenue	514488	usd
	mssv	Gross Profits GrossProfits	1125375	usd
	mssv	Percentage Of Gross Profit PercentageOfGrossProfit	0.6863	pure
CY2024Q2	us-gaap	Other Assets OtherAssets	3079586	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4037640	usd
CY2019Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.2
CY2019Q4	mssv	Aggregate Exchange Amount AggregateExchangeAmount	97252	usd
	us-gaap	Line Of Credit Facility Maximum Amount Outstanding During Period LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod	0	usd
CY2023	us-gaap	Line Of Credit Facility Maximum Amount Outstanding During Period LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod	9850	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4958	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	7679	usd
	mssv	Outstanding Convertible Notes OutstandingConvertibleNotes	0	usd
CY2023	mssv	Outstanding Convertible Notes OutstandingConvertibleNotes	9850	usd
CY2019Q4	us-gaap	Long Term Debt Term LongTermDebtTerm	P4Y
CY2019Q4	mssv	Promissory Note Premium Interest PromissoryNotePremiumInterest	0.20	pure
CY2020Q4	mssv	Penalty Penalty	5379624	usd
CY2020Q4	mssv	Aggregate Principal Amount AggregatePrincipalAmount	5379624	usd
CY2020Q4	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.15	pure
CY2020Q4	mssv	Cashless Warrants Purchased CashlessWarrantsPurchased	15000000	shares
CY2020	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	262376	usd
CY2023Q4	mssv	Secured Note Exchange SecuredNoteExchange	2506827	usd
CY2023Q4	mssv	Aggregate Consideration AggregateConsideration	300000	usd
CY2023Q4	mssv	Aggregate Principal Amount AggregatePrincipalAmount	1999999	usd
CY2023Q4	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.06	pure
CY2024Q2	us-gaap	Principal Amount Outstanding Of Loans Held In Portfolio PrincipalAmountOutstandingOfLoansHeldInPortfolio	1999999	usd
CY2023Q4	us-gaap	Principal Amount Outstanding Of Loans Held In Portfolio PrincipalAmountOutstandingOfLoansHeldInPortfolio	1999999	usd
CY2020Q4	mssv	Promissory Bebentures Lender Amount PromissoryBebenturesLenderAmount	110000	usd
CY2020Q4	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.15	pure
CY2020Q4	us-gaap	Long Term Debt Term LongTermDebtTerm	P2Y
CY2020Q4	mssv	Cashless Warrants Purchased CashlessWarrantsPurchased	1000000	shares
CY2020Q4	mssv	Advance From Lender AdvanceFromLender	100000	usd
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	10000	usd
CY2020Q4	mssv	Warrants Issued WarrantsIssued	1000000	shares
CY2021Q1	mssv	Promissory Bebentures Lender Amount PromissoryBebenturesLenderAmount	1000000	usd
CY2021Q1	mssv	Annual Interest Rate AnnualInterestRate	0.15	pure
CY2021Q1	us-gaap	Long Term Debt Term LongTermDebtTerm	P1Y
CY2021Q1	mssv	Cashless Warrants Purchased CashlessWarrantsPurchased	10000000	shares
CY2021Q1	mssv	Warrant Exercise Price WarrantExercisePrice	0.03
CY2021Q1	mssv	Advance From Lender AdvanceFromLender	900000	usd
CY2021Q1	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	100000	usd
CY2024Q2	mssv	Warrants Issued WarrantsIssued	10000000	shares
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	237811	usd
CY2021Q2	mssv	Promissory Bebentures Lender Amount PromissoryBebenturesLenderAmount	11600000	usd
CY2021Q2	mssv	Annual Interest Rate AnnualInterestRate	0.12	pure
CY2021Q2	us-gaap	Long Term Debt Term LongTermDebtTerm	P3Y
CY2021Q2	mssv	Cashless Warrants Purchased CashlessWarrantsPurchased	70000000	shares
CY2021Q2	mssv	Advance From Lender AdvanceFromLender	10500000	usd
CY2021Q2	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	1100000	usd
CY2021Q2	mssv	Warrants Issued WarrantsIssued	70000000	shares
CY2021Q2	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	5465726	usd
CY2021Q3	us-gaap	Loans And Leases Receivable Gross Carrying Amount LoansAndLeasesReceivableGrossCarryingAmount	20991	usd
CY2021Q3	mssv	Interest Rate InterestRate	0.0899	pure
CY2021Q3	mssv	Interest Monthly Payments InterestMonthlyPayments	504.94	usd
CY2021Q3	mssv	Promissory Bebentures Lender Amount PromissoryBebenturesLenderAmount	1100000	usd
CY2021Q3	mssv	Annual Interest Rate AnnualInterestRate	0.12	pure
CY2021Q3	us-gaap	Long Term Debt Term LongTermDebtTerm	P3Y
CY2021Q3	mssv	Cashless Warrants Purchased CashlessWarrantsPurchased	7500000	shares
CY2021Q3	mssv	Warrant Exercise Price WarrantExercisePrice	0.085
CY2021Q3	mssv	Advance From Lender AdvanceFromLender	1000000	usd
CY2021Q3	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	100000	usd
CY2021Q3	mssv	Warrants Issued WarrantsIssued	7500000	shares
CY2021Q3	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	360607	usd
	mssv	Outstanding Loan OutstandingLoan	7958	usd
CY2023	mssv	Outstanding Loan OutstandingLoan	7958	usd
CY2024Q2	mssv	Participating Mortgage Loan Unamortized Debt Discount Amount ParticipatingMortgageLoanUnamortizedDebtDiscountAmount	0	usd
CY2023Q4	mssv	Participating Mortgage Loan Unamortized Debt Discount Amount ParticipatingMortgageLoanUnamortizedDebtDiscountAmount	0	usd
CY2021Q4	mssv	Promissory Bebentures Lender Amount PromissoryBebenturesLenderAmount	84000	usd
CY2021Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	22162	usd
CY2021Q4	mssv	Premium Percent PremiumPercent	0.05	pure
CY2021Q4	mssv	Premium Earned PremiumEarned	111470	usd
CY2021Q4	mssv	Debt Instrument Bears Interest Rate DebtInstrumentBearsInterestRate	0.12	pure
CY2021Q4	us-gaap	Long Term Debt Term LongTermDebtTerm	P17M
	mssv	Promissory Notes Payable PromissoryNotesPayable	19722931	usd
CY2023Q4	mssv	Promissory Notes Payable PromissoryNotesPayable	19722931	usd
CY2024Q2	us-gaap	Other Deferred Costs Gross OtherDeferredCostsGross	7800	usd
CY2023Q4	us-gaap	Other Deferred Costs Gross OtherDeferredCostsGross	7800	usd
CY2024Q2	mssv	Promissory Notes Payable Discount PromissoryNotesPayableDiscount	65506	usd
CY2023Q4	mssv	Promissory Notes Payable Discount PromissoryNotesPayableDiscount	2100966	usd
CY2023Q4	us-gaap	Other Deferred Costs Net OtherDeferredCostsNet	15798	usd
CY2024Q2	us-gaap	Notes Payable NotesPayable	19665225	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	17613966	usd
	us-gaap	Interest Expense Savings Deposits InterestExpenseSavingsDeposits	2051259	usd
CY2023	us-gaap	Interest Expense Savings Deposits InterestExpenseSavingsDeposits	3049999	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1511297	usd
CY2024Q2	mssv	Outstanding Promissory Notes Payable OutstandingPromissoryNotesPayable	19730731	usd
CY2023Q4	mssv	Outstanding Promissory Notes Payable OutstandingPromissoryNotesPayable	19730731	usd
CY2024Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	124343	shares
CY2024Q2	us-gaap	Share Price SharePrice	0.035
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.06
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0501	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y6M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.998	pure
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	6944	usd
CY2023	mssv	Gain Loss On Derivative Fair Value Instruments GainLossOnDerivativeFairValueInstruments	3450	usd
CY2023	mssv	Derivative Instruments Conversions DerivativeInstrumentsConversions	1348	usd
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	2146	usd
	mssv	Gain Loss On Derivative Fair Value Instruments GainLossOnDerivativeFairValueInstruments	-2206	usd
CY2024Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	4352	usd
CY2020	mssv	Issuance Of Warrants IssuanceOfWarrants	16000000	shares
CY2021Q1	mssv	Warrants Issued For Debt WarrantsIssuedForDebt	237811	usd
CY2021Q2	mssv	Warrants Issued For Debt WarrantsIssuedForDebt	5465726	usd
CY2021Q3	mssv	Issuance Of Warrants IssuanceOfWarrants	7500000	shares
CY2021Q3	mssv	Warrants Issued For Debt WarrantsIssuedForDebt	360607	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	103500000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.082
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	16000000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.03
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	87500000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.091
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	80000000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.092
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	7500000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.091
CY2024Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1000	shares
	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	0.8
CY2022Q1	mssv	Monthly Based On Annual Rate MonthlyBasedOnAnnualRate	90000	usd
	us-gaap	Other Expenses OtherExpenses	503552	usd
CY2022Q1	mssv	Monthly Based On Annual Rate MonthlyBasedOnAnnualRate	90000	usd
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Splits StockIssuedDuringPeriodSharesStockSplits	896	shares
CY2021Q3	us-gaap	Stock Issued During Period Shares Stock Splits StockIssuedDuringPeriodSharesStockSplits	448	shares
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Splits StockIssuedDuringPeriodSharesStockSplits	448	shares
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	133470	usd
	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Assets EffectiveIncomeTaxRateReconciliationDispositionOfAssets	0.275	pure
CY2024Q2	us-gaap	Area Of Land AreaOfLand	1647	sqm
	mssv	Monthly Rent MonthlyRent	2714	usd
CY2024Q2	us-gaap	Security Deposit SecurityDeposit	5588	usd
	us-gaap	Payments For Rent PaymentsForRent	40981	usd
	us-gaap	Payments For Rent PaymentsForRent	22744	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	170302	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	166774	usd
CY2024Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	609509	usd
CY2023Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	501226	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	419470	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	308697	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	360341	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	359303	usd
	us-gaap	Depreciation Depreciation	110773	usd
	us-gaap	Depreciation Depreciation	65733	usd
CY2024Q2	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	487700	usd
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	487700	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	279926	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	231156	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	207774	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	256544	usd
CY2024Q2	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P5Y
	mssv	Amortization Expense Intellectual Property AmortizationExpenseIntellectualProperty	48770	usd
	mssv	Amortization Expense Intellectual Property AmortizationExpenseIntellectualProperty	48770	usd
	mssv	Monthly Rent MonthlyRent	2714	usd
CY2024Q2	us-gaap	Security Deposit Liability SecurityDepositLiability	5588	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	38046	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	76092	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	114138	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5980	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	108158	usd
CY2021Q3	mssv	Stock Purchase Percentage StockPurchasePercentage	1	pure
CY2021Q3	us-gaap	Cash Cash	225000	usd
	mssv	Purchase Price PurchasePrice	6229000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	5805438	usd
CY2023	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax	4125460	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1679978	usd
CY2024Q2	us-gaap	Goodwill Goodwill	1679978	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4125460	usd
CY2024Q2	us-gaap	Goodwill Goodwill	1679978	usd
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
	dei	Security Exchange Name SecurityExchangeName	NONE
CY2023Q4	us-gaap	Inventory Net InventoryNet		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12443938	shares
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023	us-gaap	Servicing Asset At Fair Value Additions ServicingAssetAtFairValueAdditions		usd
	us-gaap	Servicing Asset At Fair Value Additions ServicingAssetAtFairValueAdditions		usd
	mssv	Derivative Instruments Conversions DerivativeInstrumentsConversions		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023	mssv	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2023	mssv	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	mssv	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
	mssv	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo		usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree		usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2023	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod		usd
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod		usd
	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001760026

Files In Submission

Name	View Source	Status
0001213900-24-069065-index-headers.html	Edgar Link	pending
0001213900-24-069065-index.html	Edgar Link	pending
0001213900-24-069065.txt	Edgar Link	pending
0001213900-24-069065-xbrl.zip	Edgar Link	pending
ea0211356-10q_meso.htm	Edgar Link	pending
ea021135601ex31-1_meso.htm	Edgar Link	pending
ea021135601ex31-2_meso.htm	Edgar Link	pending
ea021135601ex32-1_meso.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mssv-20240630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mssv-20240630_cal.xml	Edgar Link	unprocessable
mssv-20240630_def.xml	Edgar Link	unprocessable
mssv-20240630_lab.xml	Edgar Link	unprocessable
mssv-20240630_pre.xml	Edgar Link	unprocessable
ea0211356-10q_meso_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RMTG
Regenerative Medical Technology Group Inc. Stock $rmtg

2024 Q3 Form 10-Q Financial Statement

#000121390024069065 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RMTG Regenerative Medical Technology Group Inc. Stock $rmtg

2024 Q3 Form 10-Q Financial Statement

#000121390024069065 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RMTG
Regenerative Medical Technology Group Inc. Stock $rmtg